Hugo Mouquet received his phD in immunology from the University of Rouen (France), following his work on the characterization of T-cell and B-cell responses in an autoimmune disease of the skin called Pemphigus. He then moved to the Rockefeller University to perform his postdoctoral trainee in the lab headed by Michel C. Nussenzweig, where he studied B-cell antibody response to HIV-1 in humans. Since 2013, Hugo Mouquet is a group leader in the immunology department of the Institut Pasteur. His lab investigates the humoral response to viruses in humans.
Patrick Wilson seminar
SEMINAIRE DU DEPARTEMENT D’IMMUNOLOGIE VENDREDI 19 MAI 2017 – 12 heures 00 Salle Jules Bordet – Bâtiment Metchnikoff – RDC Human B cell responses in the context of influenza immunity Patrick Wilson Department of […]
Think tank: B cells
The B-cell Interest Group (BIG) is a think-tank of immunologists focusing their research activities on diverse aspects of B lymphocytes and their effector molecules, antibodies. It gathers experts from the Institut Pasteur, the INEM […]
Group for AIDS Research
The Group for AIDS Research (Groupe de Réflexion SIDA, GRS) organizes monthly meetings and seminars around an HIV / AIDS research topic. Meetings and seminars are open to all. Meetings are usually held on […]
Influence of ART Timing on Mucosal B-cell Responses in HIV-1 Infected Individuals
This project in collaboration with Dr Sophie Huë (Service d’Immunologie Biologique, Hôpital Henri Mondor), and funded by Sidaction aims at understanding whether the timing of the antiretroviral therapy (ART) for AIDS treatment can positively influence B-cell / antibody responses […]
Clonal B cells in Cryoglobulinemia Vasculitis with Hepatitits C Infection
This project funded by the ANRS is a collaborative study with Dr David Saadoun (Hôpital La pitié Salpétrière, Inserm U959), which focuses on the characterization of the clonal B-cell expansions typically found in cryoglobulinemia vasculitis associated […]
Antiviral Properties of Broadly Neutralizing HIV-1 Antibodies
Broadly neutralizing HIV-1 antibodies (bNAbs) can develop in rare infected individuals several years after co-evolution with diversifying viruses. In animal models, passive immunotherapy with potent HIV-1 bNAbs has been shown to protect from infection […]
Human Antibody Responses to VirusesThe goal of this project supported by the European Research Council (Grant: ERC-2013-StG HumAntiViruses) is to study memory B-cell antibody responses to human pathogens, especially viruses, by generating and characterizing envelope […]
Methodological Approaches for Rapid Antibody Discovery
Capture of Single Antigen-Specific B cells to Produce Human Monoclonal Antibodies to Pathogens To achieve our research goals, we are making use of a very efficient method to clone and express immunoglobulins from human […]
2017Lack of ADCC breadth of human non-neutralizing anti-HIV-1 antibodies, J. Virol. 2017 Jan;.
2017Antibody 10-1074 suppresses viremia in HIV-1-infected individuals, Nat. Med. 2017 Jan;.
2016Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity, Mucosal Immunol 2016 Dec;.
2016[Antibodies that kill HIV-1-infected cells], Med Sci (Paris) 2016 8-9;32(8-9):671-4.
2016Scarcity of autoreactive human blood IgA(+) memory B cells, Eur. J. Immunol. 2016 Jul;.
2016Elimination of HIV-1-infected cells by broadly neutralizing antibodies, Nat Commun 2016;7:10844.
2016V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1, J. Acquir. Immune Defic. Syndr. 2016 Mar;71(3):237-45.
2015Tailored immunogens for rationally designed antibody-based HIV-1 vaccines, Trends Immunol. 2015 Jul;.
2015Efficient generation of human IgA monoclonal antibodies, J. Immunol. Methods 2015 Jul;422:102-10.
2015Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas, MBio 2015;6(2).
+View full list of publications